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Abstract
Objectives Bioresorbable collagen membranes are routinely
utilized in guided bone regeneration to selectively direct the
growth and repopulation of bone cells in areas of insuffi-
cient volume. However, the exact nature by which alveolar
osteoblasts react to barrier membranes as well as the effects
following the addition of growth factors to the membranes
are still poorly understood. The objective of the present
study was therefore to investigate the effect of a bioresorb-
able collagen membrane soak-loaded in growth factors bone
morphogenetic protein 2 (BMP2) or transforming growth
factor β1 (TGFβ1) on osteoblast adhesion, proliferation,
and differentiation.
Material and methods Prior to experimental seeding, mem-
branes were soaked in either BMP2 or TGFβ1 at a concen-
tration of 10 ng/ml for 5 min.
Results Human osteoblasts adhered to all soak-loaded mem-
branes as assessed by scanning electron microscopy. Growth
factors BMP2 and TGFβ1 increased osteoblast proliferation
at 3 or 5 days post-seeding when compared to control
collagen membranes. Analysis of real-time PCR revealed
that administration of BMP2 increased osteoblast differen-
tiation markers such as osterix, collagen I, and osteocalcin.
BMP2 also increased mineralization of primary osteoblasts
as demonstrated by alizarin red staining when compared to
control and TGFβ1 soak-loaded membranes.
Conclusion The combination of a collagen barrier mem-
brane with growth factors TGFβ1 and BMP2 significantly
influenced adhesion, proliferation, and differentiation of
primary human osteoblasts.
Clinical relevance The described in vitro effects following
the combination of collagen barrier membranes with growth
factors TGFβ1 and BMP2 provide further biologic support
for the clinical application of this treatment strategy in
guided bone regeneration procedures.
Keywords Barrier membranes . Growth factors . Guided
bone regeneration . GBR . GTR
Introduction
In guided tissue regeneration (GTR) and guided bone re-
generation (GBR), a barrier membrane is utilized to selec-
tively direct the growth and repopulation of periodontal
ligament and bone cells in periodontal and bone defects [1,
2]. Regenerative surgery involving the use of GTR has
proven to be an effective method for periodontal and bone
regeneration and is widely used for the treatment of peri-
odontal and bone defects [1, 3–7]. Since its first clinical use
in the early 1980s [8, 9], new innovative materials have
been designed to increase the effectiveness of the barrier
membranes. Such membranes should be capable of facili-
tating cell attachment, increasing cell proliferation, and
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promoting cell migration to the surface of the underlying
defect [10–13].
A variety of synthetic and natural bioresorbable barriers
have been fabricated and studied both in vitro and in vivo
[3–6, 14–17]. Such materials must provide biocompatibility,
tissue integration, cell occlusivity, space-making ability, and
clinical ease of use [18]. The first generation of barrier
membranes was fabricated from nonbioresorbable expanded
polytetrafluorethylen but required a second surgery to re-
move the barrier thus bearing the possibility of damaging
the newly formed tissue and increasing patient morbidity.
Chance of reinjury of the newly formed periodontal and bone
tissues combined with crestal resorption of the alveolar bone
and bacterial colonization were commonly reported [19, 20].
More recently, synthetic bioresorbable membranes were fab-
ricated primarily from polylactic, polyglycolic acids, and
collagen filaments fabricated in multiple cross-linking pat-
terns and techniques, such as ultraviolet light, glutaralde-
hyde, diphenylphosphoryl azide, and hexmethylene
diisocyanate, in order to prolong degradation of collagen
filaments by enzymatic activity of infiltrating macrophages
and leukocytes [21–27]. Many of the commercially available
GTR membranes fabricated from porcine collagens I and III
showed similar clinical results without the need of a second
surgery [3, 18, 28–30] being fully resorbable 6 months post-
surgery [14, 31].
A novel approach to GBR is the use of growth factors
which promote the regeneration of selective tissues. Of
particular relevance are the use of bone morphogenetic
protein (BMP) and transforming growth factor β
(TGFβ); both BMPs and TGFβ have been shown to
increase the proliferation and differentiation of mesenchy-
mal cells and osteoblasts in vitro [32–39] and improve
the speed and quality of new bone formation in vivo
[40–46]. In an attempt to further improve clinical out-
comes, dental clinicians recently introduced the combina-
tion of GTR barrier membrane procedures with growth
factors such as BMP2 and TGFβ1 [47–50]. However, the
exact nature by which alveolar osteoblasts react to barrier
membranes as well as the effects following addition of
growth factors to the membranes are still poorly under-
stood. Therefore, the aim of the present study was to
investigate the effect of a bioresorbable collagen mem-
brane soak-loaded in growth factors BMP2 or TGFβ1 on
osteoblast adhesion, proliferation, and differentiation.
Methods
Membrane coating with BMP2 and TGFβ1
The GTR membranes used in this study were a 30×40-mm
bioresorbable bilayer collagen membrane (Geistlich Bio-
Gide®, Wolhusen, Switzerland). It is obtained from porcine
collagen under standardized and certified procedures. For in
vitro experiments, membranes were cut under sterile con-
ditions to fit in the bottom of 24- and 6-well culture plastic
dishes. Prior to experimental seeding, membranes were
soaked in either BMP2 (Part # 892143, R&D Systems,
Minneapolis, USA) or TGFβ1 (Part # 891127, R&D Sys-
tems, Minneapolis, USA) at 10 ng/ml [51, 52] for 5 min to
simulate clinical application. All images viewed in this
study are oriented to visualize membrane sides that are
intended to guide bone regeneration as opposed to epithelial
tissue.
Osteoblast cell isolation and differentiation
Human bone chips were cultured according to an ex-
plant model [53] under signed informed consent ap-
proved by the ethics committee of the Canton of
Berne, Switzerland as previously described [54]. Prima-
ry human alveolar osteoblasts from three donors not
demonstrating any signs of periodontal disease were
detached from the tissue culture plastic using trypsin
solution (Invitrogen, Basel, Switzerland). Cells used for
experimental seeding were from passages 4–6. During
cell seeding, α-MEM medium was supplemented with
50 μg/ml ascorbic acid and 2 mM β-glycerophosphate
to promote osteoblast differentiation. Primary osteoblasts
were seeded on membranes at a density of 10,000 cells
in 24-well culture plates (Falcon, Franklin Lakes, NJ,
USA) for cell attachment, cell proliferation, and scan-
ning electron microscopy (SEM) experiments and
50,000 cells for alizarin red experiments. For PCR
experiments, cells were seeded at 100,000 cells on
membranes in six-well culture plates. For experiments
lasting longer than 5 days, medium was replaced twice
weekly.
Adhesion and proliferation assays
Primary osteoblasts were seeded on the growth factor
soak-loaded and non-loaded bioresorbable collagen
membranes in 24-well plates at a density of 10,000
cells per well. Cells were quantified using measurement
of DNA at 4 and 8 h for cell adhesion and 1, 2, 3, and
5 days for cell proliferation. At desired time points, the
cells were washed with PBS and lysed by ultrasonic
homogenization in 400 μl of 0.1 % (v/v) Triton X-100
(Sigma Aldrich, Basel, Switzerland). The DNA contents
of the cell extracts were determined using a commercial
kit including the fluorescent dye Picogreen (QuantIT,
Invitrogen) under standard protocol. Fluorescent read-
ings were performed on an Infinite 200 microplate read-
er (Tecan Group Ltd. Männedorf, Switzerland) at an
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excitation wavelength of 480 nm and an emission read-
ing of 520 nm. Experiments were performed in triplicate
with three independent experiments for each condition.
Data were analyzed for statistical significance using
two-way analysis of variance with Bonferroni test.
Scanning electron microscopy
For SEM, bioresorbable membranes were fixed in 1 %
glutaraldehyde and 1 % formaldehyde with or without
osteoblasts seeded at a density of 10,000 cells per 24-
well culture. Following dehydration with ethanol, samples
were dried to a critical point (Type M.9202 Critical Point
Dryer, Roth & Co. Hatfield, PA, USA). Next, the sam-
ples were sputtered (DCM-010, Balzers, Liechtenstein)
with a 10-nm layer of gold and analyzed microscopically
using a scanning electron microscope (XL30 FEG, Phi-
lips, Netherlands) to determine micro- and nano-
topographies of bioresorbable membrane as well as cell
shape of osteoblasts attached to membrane surfaces.
Real-time PCR
Total RNA was isolated using TRIZOL reagent and
RNAeasy Mini kit (QIAGEN, Basel, Switzerland) at
time points 3 and 10 days for osteoblast differentiation
markers. Primer and probe sequences for genes encod-
ing alkaline phosphatase (ALP, Hs01029144_m1), runt-
related transcription factor 2 (Runx2, Hs00231692_m1),
collagen1α1 (COL1A1, Hs01028970_m1), osteocalcin
(OC, Hs01587814_g1), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH, Hs03929097_g1) were pur-
chased as pre-designed gene expression assays (Applied
Biosystems, Basel, Switzerland). Real-time (RT)-PCR
was performed using 20 μl final reaction volume of
TaqMan® One-Step Master Mix kit. RNA quantification
was performed using a Nanodrop 2000c with 100 ng of
total RNA was used per sample well. All samples were
assayed in triplicate and three independent experiments
were performed. The ΔΔCt method was used to calcu-
late gene expression levels normalized to GAPDH val-
ues and calibrated to control membranes without
additional growth factors at 3 days. Data were log-
transformed prior to analysis by two-way ANOVA with
Bonferroni test using GraphPad Software v. 4 (Graph-
Pad Software, La Jolla, CA, USA).
Fig. 1 SEM analysis of
collagen barrier membrane. a, b
Membrane surface reveals
many collagen fibrils that are
intertwined with one another
with various diameters and
directions (magnification
A0×50, B0×200). c High-
resolution SEM demonstrates
collagen fibrils ranging in di-
ameter between 1 and 5 μm
(magnification0×1,600). d
Cross-sectional view of colla-
gen barrier membrane of ap-
proximately 300 μm
(magnification0×100)
Fig. 2 Attachment assay of 104 primary human osteoblasts seeded on
control, TGFβ1 soak-loaded, or BMP2 soak-loaded barrier membranes
as assessed by total dsDNA. No significant difference in cell attach-
ment could be observed for all groups at all time points
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Alizarin red quantification
Alizarin red staining was performed to determine the pres-
ence of extracellular matrix mineralization after 14 days.
Osteoblasts were seeded at a density of 50,000 cells per
24-well culture dish onto bioresorbable collagen mem-
branes. After 14 days, cells were fixed in 96 % ethanol for
15 min and stained with 0.2 % alizarin red solution in water
(pH 6.4) at room temperature for 1 h. Alizarin red was
dissolved using a solution of 20 % methanol and 10 % acetic
acid in water for 15 min. Liquid was then transferred to
cuvettes and read on a spectrophotometer at a wavelength of
450 nm. After subtraction of background, absorbance values
were normalized to DNA content. Data were analyzed for
statistical significance using one-way analysis of variance
with Tukey's test.
Results
Barrier membrane visualization
Collagen barrier membranes developed from porcine
origin are viewed in Fig. 1 by SEM. Membrane sides
intended to guide bone regeneration show a high com-
position of collagen in fibrillar form (Fig. 1a, b). High-
resolution SEM demonstrates various diameter sizes of
collagen fibrils ranging in size from 1 to 5 μm
(Fig. 1c). The cross-sectional view of collagen barrier
membranes is presented in Fig. 1d.
Adhesion of osteoblasts to barrier membranes
At 4 and 8 h post-seeding, primary human osteoblasts
adhered to collagen membranes irrespective of coating with
TGFβ1 or BMP2 displaying its excellent biocompatibility
(Fig. 2). In 4 h, osteoblasts seeded on barrier membranes
displayed near 100 % adhesion. SEM analysis of primary
osteoblasts seeded on barrier membranes was visualized at
8 h post-seeding (Fig. 3). All osteoblasts attached well on all
surfaces and displayed excellent cell spreading on each
surface (Fig. 3).
Osteoblast proliferation on barrier membranes
Osteoblast numbers were quantified at 1, 3, and 5 days post-
seeding (Fig. 4). At 1 day, no significant difference was
observed between all groups (Fig. 4). At 3 days post-
seeding, barrier membranes soak-loaded with TGFβ1 and
BMP2 displayed significant increases in cell numbers when
compared to control non-soaked barrier membranes (Fig. 4).
Similar patterns were also observed at 5 days post-seeding
with barrier membranes soak-loaded with BMP2 showing
the highest rate of proliferation at both 3 and 5 days post-
seeding (Fig. 4).
Osteoblast differentiation on barrier membranes
Osteoblasts were assessed for Runx2, OC, COL1α1, and
OSX at 3 and 14 days post-seeding. Analysis of the tran-
scription factor Runx2 gene expression showed no signifi-
cant differences in mRNA levels at 3 and 14 days for all
groups (Fig. 5a). COL1α1 mRNA levels showed signifi-
cantly higher values of mRNA at 3 and 14 days post-seeding
Fig. 4 Proliferation assay of 104 primary osteoblasts seeded on con-
trol, TGFβ1 soak-loaded, or BMP2 soak-loaded barrier membranes as
assessed by total dsDNA. (Asterisk denotes significant difference, p<
0.05)
Fig. 3 SEM analysis of primary human osteoblasts seeded on control
(a), TGFβ1 soak-loaded (b), and BMP2 soak-loaded (c) collagen
barrier membranes at 8 h post-seeding. Osteoblasts attach and spread
well on all surfaces demonstrating the excellent biocompatibility of
collagen barrier membranes with or without growth factor
incorporation
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for osteoblasts seeded on barrier membranes containing either
TGFβ1 or BMP2 (Fig. 5b). Up to a twofold increase in
COL1α1 mRNA levels was observed for BMP2 soak-
loaded barrier membranes. At 14 days post-seeding, a signif-
icant increase in mRNA expression of OC was observed for
osteoblasts seeded on BMP2-treated barrier membranes when
compared to control and TGFβ1 samples (Fig. 5c). OSX also
displayed up to a threefold increase in mRNA expression in
BMP2 soak-loaded membranes when compared to control
and TGβF1 samples (Fig. 5d). Alizarin red staining at 14 days
demonstrated significantly increased mineralization for osteo-
blasts seeded on BMP2 soak-loaded barrier membranes when
compared to control and TGFβ1 samples (Fig. 6).
Discussion
Over the past 20 years, the use of barrier membranes has
dramatically improved clinical outcomes in patients with signif-
icant bone loss [3–6]. Furthermore, the combination of barrier
membranes and different bone grafts has been shown to addi-
tionally ameliorate the results [55–57]. In the present study, the
hypothesis that additional growth factors such as TGFβ1 and
BMP2 would additionally improve the outcomes generated
from resorbable collagen barrier membranes was tested on
osteoblast adhesion, proliferation, and differentiation. Since the
majority of our understanding for the TGFβ superfamily comes
from loss-of-function studies which result in embryonic
lethality, much of our understanding of the regulatory mecha-
nisms of action for either growth factor is determined using in
vitro studies [33]. Results from the present study would support
the use of either growth factor in GTR or GBR procedures.
Previously, it has been shown that TGFβ1 enhances
osteoblast proliferation and differentiation by stimulating
expression of ALP, BSP, and osteonectin as determined by
immunohistochemistry, RT-PCR analysis, and in vitro min-
eralization [58, 59]. In the present study, it was found that
TGFβ1 had an effect on osteoblast proliferation. Still, only
limited additional benefits were observed during differenti-
ation of osteoblasts as assessed by real-time PCR experi-
ments and alizarin red staining. Interestingly, it has been
Fig. 5 Real-time PCR of
osteoblasts seeded on control,
TGFβ1 soak-loaded, and
BMP2 soak-loaded barrier
membranes for genes encoding
a Runx2, b Col1α1, c OC, and
d OSX. (Asterisk denotes sig-
nificant difference, p<0.05)
Fig. 6 Normalized alizarin red staining absorbance values at 14 days
post-seeding. BMP2 soak-loaded barrier membranes displayed signif-
icantly higher mineralization when compared to control and TGFβ1
soak-loaded barrier membranes. (Asterisk denotes significant differ-
ence, p<0.05)
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reported that primary human osteoblasts harvested from
different age groups showed that TGFβ1 had a more pro-
nounced effect on cells harvested from old patients as op-
posed to young and middle-aged patients [60].
The other growth factor tested in this study, BMP2, seems
to be the growth factor of choice for clinical application in a
variety of surgical procedures including dentistry, orthopedics,
fracture healings, and spinal fusions [61–63]. In three studies
comparing BMP2 and TGFβ1, BMP2 was able to stimulate
osteoblast proliferation and/or differentiation such as ALP and
OC in murine cell lines MC3T3-E1 and C3H10T1/2, while
TGFβ1 had a less pronounced effect [37, 64, 65]. Intriguingly,
neither BMP2 nor TGFβ1 had an effect on Runx2 in the
current study, suggesting actions independent or downstream
of this osteoblast-specific transcription factor. BMP2 induced
the expression of OSX while TGFβ1 had only moderate
effects (Fig. 5). Previously, it has been demonstrated that
BMP2 induces OSX expression through upregulation of
Dlx5 and its phosphorylation by p38 [66].
Previously, the combination of BMP2 for clinical appli-
cation has been investigated both in vivo and in clinical
trials [47–50]. Cochran et al. tested rhBMP-2 using a colla-
gen sponge carrier to stimulate bone formation in defects in
the canine mandible around endosseous dental implants.
The addition of rhBMP-2 significantly enhanced new bone
area and percentage of bone-to-implant contact after 4 and
12 weeks of healing [47]. In a subsequent study, the use of
BMP2 for patients receiving rhBMP-2 loaded in an absorb-
able collagen sponge (ACS) in human extraction sites or in
sites that required alveolar ridge augmentation demonstrated
safety 2 years following surgical implantation of rhBMP-2/
ACS (0.43 mg/ml) [48].
More recently, Sawyer et al. demonstrated in a rat model
that the release of rhBMP2 from a collagen scaffold is a
clinically applicable approach for the repair and regenera-
tion of critically sized craniofacial bone defects [49]. How-
ever, a randomized controlled clinical trial evaluating the
long-term outcome of implants placed in bone augmented
with a xenogenic bone substitute material and a collagen
membrane with or without the addition of rhBMP-2 dem-
onstrated no statistically significant differences between test
and control sites after 3 and 5 years posttreatment [50].
Results from previous animal and human studies com-
bining BMPs with collagen membranes have demonstrated
mixed outcomes [47–50, 67]. One question that remains
unresolved is the effect/use of high doses of rhBMP2 for
single application procedures. In the present in vitro study,
the local use of BMP at a concentration of 10 ng/ml was
able to stimulate an effect in primary human osteoblasts.
Previously, lower concentrations of BMP2 combined to 3D
poly(lactic-co-glycolic acid) scaffolds ranging in doses from
30 to 240 ng/mm3 were able to increase bone regeneration
in a 5-mm critical sized rat calvarial defect in a dose-
dependent manner [67]. Clinically, the use of doses ranging
from 4 to 8 mg has been reported, an increase of almost
1,000 times the concentration used in the present study.
Since collagen barrier membranes are able to adsorb growth
factor proteins, it is plausible that a lower concentration may
be required. These observations further indicate the neces-
sity to accurately administer the appropriate doses of growth
factors for specific clinical procedures. The use of an animal
model to test the effect of both TGFβ1 and BMP2 in
combination with a collagen barrier membrane is, however,
mandatory before clinical application.
In conclusion, the combination of a collagen barrier
membrane with growth factors TGFβ1 and BMP2 signifi-
cantly influenced adhesion, proliferation, and differentiation
of primary human osteoblast. All osteoblasts attached well
to membranes irrespective of additional growth factors.
Both TGFβ1 and BMP2 significantly enhanced osteoblast
proliferation while BMP2 additionally increased osteoblast
differentiation. The combination of collagen membranes
with soak-loaded growth factors may bear clinical relevance
by additionally improving healing following GBR. Further
in vivo studies are thus warranted to support the clinical
relevance of this treatment approach.
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